Their final episode of season two rounded out the theme of prevention by focusing on an area of significant impact for many of us personally and professionally. Baroness Susan Greenfield (Neuro-Bio Ltd) spoke about and explored the possibilities for preventing...
“In six months we will have the test for Alzheimer’s, and in two months, the cure!” Baroness Greenfield talks about Alzheimer’s Disease, and the focus on discovering a test and a cure! To read the full interview, with the option to translate,...
BLOWING THE MIND, EXPANDING THE MIND & LOSING THE MIND The human brain becomes highly personalized after birth by the development of unique configurations of connections between the brain cells that characterize its subsequent growth, personalizing it into what we...
Our study demonstrates that T14, a 14-mer peptide associated with Alzheimer’s disease, impairs autophagy via the mammalian target of rapamycin complex 1, contributing to the progression of the pathology. This finding adds a new layer of understanding to how T14...
Our team has demonstrated that oxidative stress, triggered by high glucose, increases T14 peptide levels in vitro and reduces cell viability. The cyclic form of T14, NBP14, blocked these toxic effects, suggesting its potential as a therapeutic agent. These findings...
Sara Garcia Ratés, CSO at Neuro-Bio, will be representing Neuro-Bio together with members of other industries such Big Pharma in this collaboration of academia and industry. The board will provide advice and support to develop the University curriculum, initiate more...
